IFN-γ selectively exerts pro-apoptotic effects on tumor-initiating label-retaining colon cancer cells

Cancer Letters

Volumn 336, Issue 1, 2013, Pages 174-184

  Ni, Chao ^a   Wu, Ping ^a   Zhu, Xiaotao ^b   Ye, Jun ^a   Zhang, Zhigang ^a   Chen, Zhigang ^a   Zhang, Ting ^c   Zhang, Tao ^a   Wang, Ke ^a   Wu, Dang ^a   Qiu, Fuming ^c   Huang, Jian ^a,c  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Jinhua Central Hospital   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Cancer stem cells; Interferon gamma; Lgr5; Quiescent cancer cells

Indexed keywords

GAMMA INTERFERON RECEPTOR; OXALIPLATIN; RECOMBINANT GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL SUBPOPULATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LABEL RETAINING CANCER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CELL SEPARATION; CELL SURVIVAL; COLONIC NEOPLASMS; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; ORGANOPLATINUM COMPOUNDS; RECEPTORS, G-PROTEIN-COUPLED; STEM CELLS;

EID: 84879000385     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.04.029     Document Type: Article

References (54)

1. Yeung T.M., Gandhi S.C., Wilding J.L., Muschel R., Bodmer W.F. Cancer stem cells from colorectal cancer-derived cell lines. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:3722-3727.
2. Lin S.P., Lee Y.T., Yang S.H., Miller S.A., Chiou S.H., Hung M.C., Hung S.C. Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis. Cancer Letters 2013, 328:226-234.
3. Shmelkov S.V., Butler J.M., Hooper A.T., Hormigo A., Kushner J., Milde T., St Clair R., Baljevic M., White I., Jin D.K., Chadburn A., Murphy A.J., Valenzuela D.M., Gale N.W., Thurston G., Yancopoulos G.D., D'Angelica M., Kemeny N., Lyden D., Rafii S. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. The Journal of Clinical Investigation 2008, 118:2111-2120.
4. Stuelten C.H., Mertins S.D., Busch J.I., Gowens M., Scudiero D.A., Burkett M.W., Hite K.M., Alley M., Hollingshead M., Shoemaker R.H., Niederhuber J.E. Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 2010, 28:649-660.
5. Nian W.Q., Chen F.L., Ao X.J., Chen Z.T. CXCR4 positive cells from Lewis lung carcinoma cell line have cancer metastatic stem cell characteristics. Molecular and Cellular Biochemistry 2011, 355:241-248.
6. Pang R., Law W.L., Chu A.C., Poon J.T., Lam C.S., Chow A.K., Ng L., Cheung L.W., Lan X.R., Lan H.Y., Tan V.P., Yau T.C., Poon R.T., Wong B.C. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010, 6:603-615.
7. O'Brien C.A., Kreso A., Ryan P., Hermans K.G., Gibson L., Wang Y., Tsatsanis A., Gallinger S., Dick J.E. ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell 2012, 21:777-792.
8. Kamohara Y., Haraguchi N., Mimori K., Tanaka F., Inoue H., Mori M., Kanematsu T. The search for cancer stem cells in hepatocellular carcinoma. Surgery 2008, 144:119-124.
9. Kusumbe A.P., Bapat S.A. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Research 2009, 69:9245-9253.
10. Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., Parada L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012.
11. Yan K.S., Chia L.A., Li X., Ootani A., Su J., Lee J.Y., Su N., Luo Y., Heilshorn S.C., Amieva M.R., Sangiorgi E., Capecchi M.R., Kuo C.J. The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:466-471.
12. Kobayashi S., Yamada-Okabe H., Suzuki M., Natori O., Kato A., Matsubara K., Chen Y.J., Yamazaki M., Funahashi S., Yoshida K., Hashimoto E., Watanabe Y., Mutoh H., Ashihara M., Kato C., Watanabe T., Yoshikubo T., Tamaoki N., Ochiya T., Kuroda M., Levine A.J., Yamazaki T. LGR5-positive colon cancer stem cells interconvert with drug resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells 2012.
13. Wei J., Barr J., Kong L.Y., Wang Y., Wu A., Sharma A.K., Gumin J., Henry V., Colman H., Sawaya R., Lang F.F., Heimberger A.B. Glioma-associated cancer-initiating cells induce immunosuppression. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16:461-473.
14. Schatton T., Schutte U., Frank N.Y., Zhan Q., Hoerning A., Robles S.C., Zhou J., Hodi F.S., Spagnoli G.C., Murphy G.F., Frank M.H. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Research 2010, 70:697-708.
15. Moserle L., Indraccolo S., Ghisi M., Frasson C., Fortunato E., Canevari S., Miotti S., Tosello V., Zamarchi R., Corradin A., Minuzzo S., Rossi E., Basso G., Amadori A. The side population of ovarian cancer cells is a primary target of IFN-α antitumor effects. Cancer Research 2008, 68:5658-5668.
16. Yuki K., Natsume A., Yokoyama H., Kondo Y., Ohno M., Kato T., Chansakul P., Ito M., Kim S.U., Wakabayashi T. Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling. Cancer Letters 2009, 284:71-79.
17. Beatty G., Paterson Y. IFN-γ-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-γ. Journal of Immunology 2001, 166:2276-2282.
18. Chawla-Sarkar M., Lindner D.J., Liu Y.F., Williams B.R., Sen G.C., Silverman R.H., Borden E.C. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis: An International Journal on Programmed Cell Death 2003, 8:237-249.
19. Brown T.J., Lioubin M.N., Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. Journal of Immunology 1987, 139:2977-2983.
20. Marth C., Windbichler G.H., Hausmaninger H., Petru E., Estermann K., Pelzer A., Mueller-Holzner E. Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 2006, 16:1522-1528.
21. Wall L., Burke F., Smyth J.F., Balkwill F. The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo. Gynecologic Oncology 2003, 88:S149-S151.
22. Matsushita K., Takenouchi T., Shimada H., Tomonaga T., Hayashi H., Shioya A., Komatsu A., Matsubara H., Ochiai T. Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: possible involvement of c-myc suppression by interferon-gamma in situ. Cancer Science 2006, 97:57-63.
23. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. Journal of Leukocyte Biology 2004, 75:163-189.
24. George J., Banik N.L., Ray S.K. Combination of hTERT knockdown and IFN-γ treatment inhibited angiogenesis and tumor progression in glioblastoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15:7186-7195.
25. Janardhanan R., Banik N.L., Ray S.K. N-(4-Hydroxyphenyl) retinamide induced differentiation with repression of telomerase and cell cycle to increase interferon-gamma sensitivity for apoptosis in human glioblastoma cells. Cancer Letters 2008, 261:26-36.
26. George J., Banik N.L., Ray S.K. Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines. The International Journal of Biochemistry and Cell Biology 2010, 42:1164-1173.
27. Lobo N.A., Shimono Y., Qian D., Clarke M.F. The biology of cancer stem cells. Annual Review of Cell and Developmental Biology 2007, 23:675-699.
28. Wang K., Liu L., Zhang T., Zhu Y.L., Qiu F., Wu X.G., Wang X.L., Hu F.Q., Huang J. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer. International Journal of Nanomedicine 2011, 6:3207-3218.
29. Wang Y.K., Zhu Y.L., Qiu F.M., Zhang T., Chen Z.G., Zheng S., Huang J. Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis 2010, 31:1376-1380.
30. Lin L., Liu A., Peng Z., Lin H.J., Li P.K., Li C., Lin J. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Research 2011, 71:7226-7237.
31. Huang E.H., Hynes M.J., Zhang T., Ginestier C., Dontu G., Appelman H., Fields J.Z., Wicha M.S., Boman B.M. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SCs) and tracks SC overpopulation during colon tumorigenesis. Cancer Research 2009, 69:3382-3389.
32. Vermeulen L., Todaro M., de Sousa Mello F., Sprick M.R., Kemper K., Perez Alea M., Richel D.J., Stassi G., Medema J.P. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:13427-13432.
33. Jaks V., Barker N., Kasper M., van Es J.H., Snippert H.J., Clevers H., Toftgard R. Lgr5 marks cycling, yet long-lived, hair follicle stem cells. Nature Genetics 2008, 40:1291-1299.
34. Xu Q., Liu G., Yuan X., Xu M., Wang H., Ji J., Konda B., Black K.L., Yu J.S. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 2009, 27:1734-1740.
35. Xiao Z.Y., Tang H., Xu Z.M., Yan Z.J., Li P., Cai Y.Q., Jiang X.D., Xu R.X. An experimental study of dendritic cells transfected with cancer stem-like cells RNA against 9L brain tumors. Cancer Biology and Therapy 2011, 11:974-980.
36. Bernabei P., Coccia E.M., Rigamonti L., Bosticardo M., Forni G., Pestka S., Krause C.D., Battistini A., Novelli F. Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. Journal of Leukocyte Biology 2001, 70:950-960.
37. Xin H.W., Hari D.M., Mullinax J.E., Ambe C.M., Koizumi T., Ray S., Anderson A.J., Wiegand G.W., Garfield S.H., Thorgeirsson S.S., Avital I. Tumor-initiating label-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division. Stem Cells 2012, 30:591-598.
38. Bragado P., Estrada Y., Sosa M.S., Avivar-Valderas A., Cannan D., Genden E., Teng M., Ranganathan A.C., Wen H.C., Kapoor A., Bernstein E., Aguirre-Ghiso J.A. Analysis of marker-defined HNSCC subpopulations reveals a dynamic regulation of tumor initiating properties. PloS One 2012, 7:e29974.
39. Xue Z., Yan H., Li J., Liang S., Cai X., Chen X., Wu Q., Gao L., Wu K., Nie Y., Fan D. Identification of cancer stem cells in vincristine preconditioned SGC7901 gastric cancer cell line. Journal of Cellular Biochemistry 2012, 113:302-312.
40. Dembinski J.L., Krauss S. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clinical and Experimental Metastasis 2009, 26:611-623.
41. Roesch A., Fukunaga-Kalabis M., Schmidt E.C., Zabierowski S.E., Brafford P.A., Vultur A., Basu D., Gimotty P., Vogt T., Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594.
42. Pece S., Tosoni D., Confalonieri S., Mazzarol G., Vecchi M., Ronzoni S., Bernard L., Viale G., Pelicci P.G., Di Fiore P.P. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73.
43. Ishimoto T., Oshima H., Oshima M., Kai K., Torii R., Masuko T., Baba H., Saya H., Nagano O. CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Science 2010, 101:673-678.
44. Deleyrolle L.P., Harding A., Cato K., Siebzehnrubl F.A., Rahman M., Azari H., Olson S., Gabrielli B., Osborne G., Vescovi A., Reynolds B.A. Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain: A Journal of Neurology 2011, 134:1331-1343.
45. Montgomery R.K., Carlone D.L., Richmond C.A., Farilla L., Kranendonk M.E., Henderson D.E., Baffour-Awuah N.Y., Ambruzs D.M., Fogli L.K., Algra S., Breault D.T. Mouse telomerase reverse transcriptase (mTert) expression marks slowly cycling intestinal stem cells. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:179-184.
46. Sangiorgi E., Capecchi M.R. Bmi1 is expressed in vivo in intestinal stem cells. Nature Genetics 2008, 40:915-920.
47. Powell A.E., Wang Y., Li Y., Poulin E.J., Means A.L., Washington M.K., Higginbotham J.N., Juchheim A., Prasad N., Levy S.E., Guo Y., Shyr Y., Aronow B.J., Haigis K.M., Franklin J.L., Coffey R.J. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 2012, 149:146-158.
48. Yan K.S., Chia L.A., Li X., Ootani A., Su J., Lee J.Y., Su N., Luo Y., Heilshorn S.C., Amieva M.R., Sangiorgi E., Capecchi M.R., Kuo C.J. The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proceedings of the National Academy of Sciences of the United States of America 2011.
49. Gupta P.B., Fillmore C.M., Jiang G., Shapira S.D., Tao K., Kuperwasser C., Lander E.S. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011, 146:633-644.
50. Schepers A.G., Snippert H.J., Stange D.E., van den Born M., van Es J.H., van de Wetering M., Clevers H. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012.
51. Driessens G., Beck B., Caauwe A., Simons B.D., Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012.
52. Novelli F., Bernabei P., Ozmen L., Rigamonti L., Allione A., Pestka S., Garotta G., Forni G. Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-γ is correlated with the differential expression of the alpha- and beta-chains of its receptor. Journal of Immunology 1996, 157:1935-1943.
53. Bernabei P., Allione A., Rigamonti L., Bosticardo M., Losana G., Borghi I., Forni G., Novelli F. Regulation of interferon-gamma receptor (INF-γR) chains: a peculiar way to rule the life and death of human lymphocytes. European Cytokine Network 2001, 12:6-14.
54. Windbichler G.H., Hausmaninger H., Stummvoll W., Graf A.H., Kainz C., Lahodny J., Denison U., Muller-Holzner E., Marth C. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. British Journal of Cancer 2000, 82:1138-1144.